1. Volume 130, Issue 1, Pages 252-253 (July 2013)
Corrigendum to “A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study” [Gynecol Oncol 127 (2012) 538–543] 
Robert L. Coleman, Michael W. Sill, Heather A. Lankes, Amanda Nickles Fader, Neil J. Finkler, James S. Hoffman, Peter G. Rose, Gregory P. Sutton, Charles W. Drescher, D. Scott McMeekin, Wei Hu, Michael Deavers, Andrew K. Godwin, R. Katherine Alpaugh, Anil K. Sood 
Gynecologic Oncology 
Volume 130, Issue 1, Pages (July 2013)
DOI: /j.ygyno
Copyright © 2013 Elsevier Inc. Terms and Conditions

2. Fig. 1
Kaplan–Meier plots depicting the progression-free and overall survival for the 44 evaluable patients on this trial.
Gynecologic Oncology  , DOI: ( /j.ygyno )
Copyright © 2013 Elsevier Inc. Terms and Conditions